Top Page
EVE Health Group Limited
(Sydney:EVE)
EVE Health Group Limited (EVE) vs. iShares MSCI Australia ETF (EWA)
EVE Health Group Limited Business Overview & Revenue Model
EVE Health Group Limited Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.73M | 1.73M | 2.13M | 2.33M | 2.01M | 2.80M |
| Gross Profit | 824.03K | 824.03K | 876.96K | 827.83K | -1.00M | -713.50K |
| EBITDA | -1.45M | -1.43M | -1.51M | -2.18M | -4.53M | -2.79M |
| Net Income | -1.58M | -1.58M | -1.90M | -4.04M | -5.37M | -3.63M |
Balance Sheet | ||||||
| Total Assets | 4.12M | 4.12M | 2.52M | 4.13M | 8.07M | 11.92M |
| Cash, Cash Equivalents and Short-Term Investments | 903.42K | 903.42K | 106.17K | 192.48K | 1.10M | 3.16M |
| Total Debt | 91.28K | 91.28K | 74.85K | 4.28K | 492.39K | 1.01M |
| Total Liabilities | 572.45K | 572.45K | 1.30M | 1.01M | 1.14M | 1.74M |
| Stockholders Equity | 3.55M | 3.55M | 1.22M | 3.12M | 6.93M | 10.19M |
Cash Flow | ||||||
| Free Cash Flow | -1.62M | -1.62M | -1.11M | -1.65M | -3.80M | -2.51M |
| Operating Cash Flow | -1.62M | -1.62M | -1.11M | -1.65M | -3.77M | -2.24M |
| Investing Cash Flow | 2.13M | 2.13M | 874.27K | 498.46K | -26.05K | -263.38K |
| Financing Cash Flow | 279.09K | 279.09K | 146.37K | 240.69K | 1.74M | 529.43K |
EVE Health Group Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
43 Neutral | AU$33.11M | 39.13 | ― | ― | 6.76% | ― | |
43 Neutral | ― | ― | ― | ― | ― | 27.69% | |
42 Neutral | AU$9.90M | -2.78 | -77.48% | ― | 63.30% | 70.00% | |
41 Neutral | AU$6.55M | -2.02 | -60.84% | ― | -18.70% | 20.83% | |
37 Underperform | AU$9.18M | ― | -555.97% | ― | 88.48% | 51.61% | |
31 Underperform | AU$4.50M | -0.64 | ― | ― | -21.84% | 79.99% |
EVE Health Group Limited Corporate Events
EVE Health Group Limited announced the issuance of 11,300,000 new unquoted equity securities, specifically options exercisable at 6 cents and expiring on December 31, 2028. This move is part of an employee incentive scheme, which could potentially enhance employee engagement and align their interests with the company’s growth objectives.
EVE Health Group Limited has announced the issuance of 22,999,998 unquoted securities, which are options exercisable at 6 cents and set to expire on December 31, 2027. This issuance is part of a previously announced transaction, indicating strategic financial maneuvers that may impact the company’s market positioning and stakeholder interests.
EVE Health Group announced that all resolutions proposed at its General Meeting on December 4, 2025, were successfully passed by a poll. This outcome supports the company’s strategic initiatives, including the ratification and approval of various securities and options, which are expected to strengthen its market position and facilitate the commercialization of its innovative pharmaceutical products.
EVE Health Group Limited has announced a change in the director’s interest notice for Stuart Gunzburg. The change involves an off-market transfer of 20,502,645 ordinary shares, which were previously held indirectly through CBLW Pty Ltd. This transfer is part of a Deed of Settlement, and the shares will remain under voluntary escrow until June 12, 2026. This adjustment in shareholding does not involve any cash consideration and reflects a strategic realignment of interests within the company’s leadership.
EVE Health Group Limited has announced the launch of two innovative products: Dyspro, a fast-acting non-hormonal gummy for menstrual pain, and Libbo, a rapid-onset oral strip for erectile dysfunction. These products target the large, underserved global markets for dysmenorrhoea and erectile dysfunction, valued at US$10.92 billion and US$5.31 billion respectively. The company’s patent-pending nano-emulsion technology enhances the speed and effectiveness of these formulations. Dyspro has already been launched in Australia, with Libbo expected to follow in December, marking a significant step in the company’s commercialisation efforts.
EVE Health Group Limited has signed a Patient Support Telehealth Services Agreement with hubMed Pty Ltd to enhance care for patients using its products, Dyspro™ and Libbo™, for women’s and men’s health conditions. This agreement aims to improve continuity of care and patient confidence by providing accessible telehealth consultations with registered nurses, reinforcing the safe use of EVE’s therapies. The initiative is expected to address significant unmet needs in both women’s and men’s health, potentially improving patient outcomes and adherence to treatment.
EVE Health Group Limited has signed a Patient Support Telehealth Services Agreement with hubMed Pty Ltd to enhance care for patients using EVE’s products for women’s and men’s health conditions. This partnership aims to improve continuity of care through regular telehealth consultations, supporting patient adherence and timely clinical guidance. The initiative is expected to strengthen EVE’s market positioning by providing better patient outcomes and expanding their digital ecosystem to support product launches.
EVE Health Group announced that all resolutions presented at its Annual General Meeting were passed by a poll. This includes the adoption of the remuneration report, the re-election of a director, approval of an additional 10% capacity, and the issuance of securities under an employee incentive plan. These decisions reflect strong shareholder support and could positively impact the company’s strategic initiatives and market positioning.
EVE Health Group Limited has announced a General Meeting of Shareholders to be held on December 4, 2025, in Subiaco, Western Australia. Shareholders are encouraged to participate by attending in person or voting by proxy, with proxy forms to be submitted 48 hours prior to the meeting. This meeting is a crucial event for shareholders to engage with the company’s governance and decision-making processes.
EVE Health Group Limited has announced the issuance of up to 12,300,000 unlisted options to key personnel and directors as part of its Employee Incentive Plan. This initiative aims to align compensation with shareholder value creation, support talent retention, and focus on achieving key commercial and regulatory milestones in its health portfolios. The options, which require shareholder approval for directors, have specific vesting conditions tied to service and performance targets, including share price milestones and product registrations.
EVE Health Group Limited has appointed its first dedicated Medical Science Liaison (MSL) to lead national medical education and engagement programs, marking a significant step in its commercial rollout strategy. This appointment aims to build confidence among prescribers and broaden patient access to EVE’s products, Dyspro™ and Libbo™, with plans to expand the MSL team throughout 2026, enhancing the company’s medical capability and supporting its growth in the pharmaceutical industry.
EVE Health Group Limited announced significant progress in the commercial rollout of its products Dyspro™ and Libbo™. The company has completed the first patient prescriptions for Dyspro™, a cannabinoid-based gummy for women’s health issues, and placed its first commercial order for Libbo™, an oral dissolving film for erectile dysfunction. EVE has also launched an online platform, Reclaim My Cycle, to support women’s health education and prescriber resources. Additionally, a $1.1 million placement was completed to accelerate these initiatives, and a Scientific Advisory Board was established to guide the company’s evidence-based strategy.
EVE Health Group Limited has announced a target market determination for the issuance of free attaching options related to a placement offer of shares to sophisticated investors. The options, which include Attaching Placement Options, Lead Manager Options, and Attaching Corporate Adviser Options, are designed for investors seeking exposure to the company’s growth in the health and pharmaceutical sectors. These options are part of a strategy to raise $1,100,000 through a share placement, with the potential for capital growth and inclusion in a diversified portfolio for medium to long-term investment. The options are not intended to be quoted, and the company emphasizes the importance of consulting the prospectus and professional advisers before making investment decisions.
EVE Health Group Limited has issued a prospectus detailing several offers, including the issuance of 36,666,667 Placement Shares to raise $1,100,000, alongside options for placement subscribers and corporate advisers. These offers are subject to shareholder approval and are aimed at enhancing the company’s financial position and market presence. The prospectus is a transaction-specific document prepared in accordance with the Corporations Act, and it highlights the importance of potential investors considering their financial objectives and risks before investing.
EVE Health Group Limited has announced a proposed issue of securities, including options exercisable at AUD 6 cents expiring in two years, and ordinary fully paid shares. This move is part of a placement or other type of issue, potentially impacting the company’s financial strategy and market positioning.
EVE Health Group Limited has successfully raised $1.1 million through a placement to sophisticated and professional investors, exceeding their initial target due to strong investor demand. The funds will be used to accelerate the commercial rollout of their lead pharmaceutical products, Dyspro and Libbo, by expanding prescriber education programs, growing distribution networks, and supporting marketing and patient access initiatives. This financial boost is expected to enhance EVE’s market positioning and facilitate the progression to TGA Export-Only status and full TGA registration, reflecting strong confidence in the company’s strategy to transform treatment in women’s and men’s health.
EVE Health Group Limited has requested a trading halt on its securities as it plans to consider, plan, and execute a capital raising. The trading halt will remain in effect until either the start of normal trading on 9 October 2025 or when the company makes an announcement regarding the capital raising. This move indicates EVE’s strategic financial planning and could impact its market operations and stakeholder interests.
EVE Health Group Limited has announced its Annual General Meeting (AGM) for shareholders, scheduled to take place on November 5, 2025, in Subiaco, Western Australia. Shareholders are encouraged to participate by attending in person or voting by proxy, with proxy forms to be submitted 48 hours prior to the meeting. This AGM is a significant event for the company, providing a platform for shareholder engagement and decision-making on key corporate matters.
EVE Health Group Limited has announced the launch of two innovative products, Dyspro and Libbo, targeting the global dysmenorrhoea and erectile dysfunction markets, valued at US$10.92B and US$5.31B respectively. With its patent-pending nano-emulsion technology, the company aims to improve drug delivery speed and effectiveness, having already commenced sales of Dyspro in Australia, with Libbo expected to follow in December.
EVE Health Group announced that its incoming CEO, Mr. Damian Wood, will present at the ShareCafe Small Cap ‘Sip and Learn’ Webinar on September 25, 2025. This presentation marks a significant engagement opportunity for the company, potentially impacting its market visibility and stakeholder relations positively.
EVE Health Group Limited has announced the successful manufacture and distribution of Dyspro™, a cannabinoid-based gummy designed to address dysmenorrhoea and endometriosis, two significant women’s health issues. The product is now available for prescription through TeleDocs’ telehealth network, with additional distribution pathways being explored. This launch marks a pivotal moment for EVE as it aims to meet the substantial unmet medical needs in this market, which is expected to grow significantly in the coming years.
EVE Health Group Limited has announced that its next Annual General Meeting (AGM) will be held on or about November 6, 2025, with the re-election of directors as a key agenda item. The deadline for director nominations is set for September 18, 2025. This announcement is crucial for stakeholders as it outlines the timeline for potential changes in the company’s leadership, which could impact its strategic direction and operations.